Executive Briefing Series (formerly The Food & Drug Letter)

The finalized FDA user fee bill requires early notification on manufacturing changes that could create drug shortages, but the language is so vague that drugmakers will flood the agency with reports, causing more harm than good, a former FDA associate commissioner says.